Skip to main content
Top
Published in: Reactions Weekly 1/2015

01-04-2015 | Case report

Ambrisentan/beraprost/bosentan/sildenafil

Various toxicities: 3 case reports

Published in: Reactions Weekly | Issue 1/2015

Login to get access

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literature
go back to reference Kuwana M, et al. Complex pathophysiology of pulmonary hypertension associated with systemic sclerosis: Merits and demerits of aggressive treatment with pulmonary vasodilators. Clinical and Experimental Rheumatology 32 (Suppl. 81): S137-S138 abstr. PS333, 2014. Available from: URL: http://www.clinexprheumatol.org/a.asp?IDArchivio=156 [abstract] - Japan Kuwana M, et al. Complex pathophysiology of pulmonary hypertension associated with systemic sclerosis: Merits and demerits of aggressive treatment with pulmonary vasodilators. Clinical and Experimental Rheumatology 32 (Suppl. 81): S137-S138 abstr. PS333, 2014. Available from: URL: http://​www.​clinexprheumatol​.​org/​a.​asp?​IDArchivio=​156 [abstract] - Japan
Metadata
Title
Ambrisentan/beraprost/bosentan/sildenafil
Various toxicities: 3 case reports
Publication date
01-04-2015
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2015
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-015-9112-4

Other articles of this Issue 1/2015

Reactions Weekly 1/2015 Go to the issue

Case report

Sitagliptin

Case report

Methotrexate

Case report

Lisinopril

Case report

Doxycycline

Case report

Sorafenib